How Chronic Stress Feeds Liver Cancer: A Brain-Liver Loop Revealed in Mice

Chronic stress has long been suspected of whispering encouragement to cancer, but the actual wiring behind that whisper has remained stubbornly obscure. Now a team at Sun Yat-sen University Cancer Center in Guangzhou has traced one of the most complete neural circuits yet to connect emotional suffering with tumor growth. Writing in Nature Communications, Kun Zhang, Jianxing Zhang, Dongmei Chi, Zhaoli He, Sudena Wang and colleagues, led by Weian Zeng, Handong Ouyang, Chaopeng Ou and Xiaohui Bai, show that in male mice, chronic stress switches on a specific hypothalamic-vagal pathway that bathes liver tumors in acetylcholine, accelerates hepatocellular carcinoma progression, and even feeds back to the brain to worsen depression-like behaviors. The study, published on 24 September 2026, maps a closed loop between liver and brain that could finally explain why depression and liver cancer so often travel together.

Hepatocellular carcinoma, the most common form of primary liver cancer, is a disease in which psychological state and clinical outcome have repeatedly been correlated but rarely connected mechanistically. Patients with liver cancer experience depression at strikingly high rates, and depression, in turn, has been associated with poorer survival in multiple cancer types. What has been missing is a concrete anatomical and molecular route by which a mental state could change the biology of a tumor. The new work addresses that gap by combining circuit neuroscience, single-cell transcriptomics and tumor biology in a single experimental framework, asking not just whether stress matters for cancer, but which neurons carry the signal and which molecules deliver it.

The team began with a broad observation: in male mice, chronic stress, systemic inflammation and neuropathic pain were all associated with faster hepatocellular carcinoma progression. Rather than treating stress as a diffuse hormonal phenomenon, the researchers focused on a precisely defined pathway. Chronic stress, they found, hyperactivates glutamatergic neurons in the paraventricular nucleus of the hypothalamus, a master hub of the stress response. These neurons project to the dorsal motor nucleus of the vagus, where they drive cholinergic vagal motor neurons whose fibers reach the liver. The result of this hypothalamus-to-vagus-to-liver relay is a measurable increase in acetylcholine inside the tumor microenvironment, a neurotransmitter arriving not from the bloodstream but along a dedicated neural line from the brain.

To find out what that acetylcholine actually does inside the tumor, the researchers turned to single-cell transcriptomics, profiling the gene-expression identities of individual cells within hepatocellular carcinomas. Among the acetylcholine-responsive population, one cell type stood out: epithelial cells carrying the receptor subunit CHRNA9, also known as the nicotinic acetylcholine receptor subunit alpha-9. These Chrna9-positive epithelial cells were not acting alone. The single-cell data revealed that they communicate with tumor-associated macrophages through a signaling axis involving the collagen proteins COL1A1 and COL1A2, the adhesion molecule CD44, and the transcription factor STAT3. That interaction prompts the macrophage compartment to produce CXCL1, a chemokine best known for recruiting neutrophils and amplifying inflammatory signaling.

The chemokine turned out to be a pivotal node in the pathology. CXCL1 did more than shape the immune landscape of the tumor; acetylcholine also acted directly on tumor cells through CHRNA9 to promote their proliferation, giving the neurotransmitter both a direct growth-promoting role and an indirect inflammatory one. More surprising still was where some of the CXCL1 ended up. The team found that circulating CXCL1 can cross the blood-brain barrier and activate glutamatergic neurons in the hypothalamus, the very region where the circuit begins. In the animals, this liver-to-brain leg of the loop manifested as exacerbated depression-like behaviors, closing a feedback circle in which stress promotes tumor growth, the tumor broadcasts inflammatory signals back to the brain, and those signals deepen the depressive state that started the cycle.

Perhaps the most clinically provocative part of the study is what happened when the researchers interrupted the loop at different points. Silencing the hypothalamic vagal circuit restrained tumor progression. So did knocking down Chrna9 specifically in tumor cells, and so did systemic neutralization of CXCL1 with blocking antibodies. Crucially, these interventions did not merely slow the cancer; they also alleviated the depression-like behaviors in the mice. A single molecular target, in other words, sat at the intersection of two seemingly separate diseases, suggesting that the comorbidity of liver cancer and depression may not be a coincidence of suffering but a shared physiology with shared points of attack.

The technical achievement underlying these conclusions is considerable. Mapping a hypothalamic circuit requires the ability to identify, manipulate and monitor specific neuronal populations, and the study’s use of circuit-tracing and silencing approaches allowed the authors to establish causality rather than mere correlation. The single-cell transcriptomic analysis then bridged scales, moving from the whole-animal level of behavior and tumor volume down to the molecular conversations between individual epithelial cells and macrophages. By demonstrating that the COL1A1/2-CD44-STAT3 axis mediates the epithelial-macrophage crosstalk, the researchers provided a mechanistic handle on how a neural signal, acetylcholine, is transduced into an inflammatory output, CXCL1, that reshapes both tumor and brain.

Several caveats deserve emphasis. All of the findings come from male mice, and the authors are explicit about this sex limitation in the title of the paper itself; whether the same hypothalamic vagal circuit operates in female animals, in which both stress physiology and liver cancer biology can differ, remains an open question. Mouse models of hepatocellular carcinoma, moreover, do not fully recapitulate the human disease, which typically arises on a backdrop of cirrhosis, viral hepatitis or metabolic dysfunction. The link between chronic stress and tumor progression in humans is supported by epidemiological associations but has never been demonstrated through a defined neural circuit, and translating circuit-level interventions from mice to patients would face formidable technical and ethical hurdles. The blood-brain barrier crossing of CXCL1, while demonstrated in this model, would also need careful validation in human cancer patients with depression.

Even with those limitations, the conceptual implications are substantial. The study reframes the relationship between mental state and cancer as a bidirectional physiological loop rather than a one-way influence. Stress activates a brain-to-liver neural pathway; the tumor responds by growing and by releasing inflammatory mediators; those mediators return to the brain and deepen the behavioral state that drove the circuit in the first place. Each leg of the loop offers a potential intervention point, from neuromodulation of hypothalamic output to receptor-targeted drugs acting on CHRNA9 to cytokine-neutralizing therapies aimed at CXCL1. The finding that blocking any of these nodes improved both tumor outcomes and mood-related behaviors hints at a future in which oncology and psychiatry share therapeutic targets.

For the millions of people living with hepatocellular carcinoma, and for the large fraction of them who also experience depression, the work offers something more than a molecular diagram: it offers a rationale. If chronic stress genuinely accelerates liver cancer through a named circuit and named molecules, then managing stress, inflammation and neural signaling ceases to be a matter of comfort and becomes a matter of tumor biology. The Guangzhou team’s circuit, running from the paraventricular hypothalamus through the vagus into the tumor and back again, is likely to inspire a wave of studies asking whether similar brain-to-organ loops govern other cancers, and whether the liver-brain axis they uncovered can be safely pharmacologically severed in patients. The feedback loop between despair and disease, this research suggests, may be far more literal than medicine has assumed.

Subject of Research: Neural and immune mechanisms linking chronic stress to hepatocellular carcinoma progression and depression-like behavior in male mice

Article Title: Chronic stress activates a hypothalamic vagal circuit to promote hepatocellular carcinoma progression in male mice

Article References: Zhang, K., Zhang, J., Chi, D., He, Z., Wang, S., Zheng, X., Guo, R., Zeng, W., Ouyang, H., Ou, C., & Bai, X. (2026). Chronic stress activates a hypothalamic vagal circuit to promote hepatocellular carcinoma progression in male mice. Nature Communications. https://doi.org/10.1038/s41467-026-77923-0

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77923-0

Keywords: chronic stress, hepatocellular carcinoma, hypothalamus, vagus nerve, acetylcholine, CHRNA9, CXCL1, liver-brain axis, depression, tumor microenvironment, macrophages, single-cell transcriptomics